{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"Number of patients who complete the planned treatment","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"18 months","title":"Completion Rate","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}